Cipla's subsidiary to acquire US-based Avenue Therapeutics for $ 215 million

At the second stage, InvaGen or its affiliates will acquire the remaining shares of Avenue's common stock, for up to USD 180 million in the aggregate.

Source: The Economic Times Healthcare and Biotech News - November 13, 2018 Category: Pharmaceuticals Source Type: news